Table 3.
Delivery of CRISPR-Cas9 RNP by EVs
Method | EV source | Target organ/cells | Target gene | Loading method | Reference |
---|---|---|---|---|---|
Pre-isolation | Expi293F-derived EVs | HEK293T | fluorescent protein | transfection (PEI Max) | Osteikoetxea et al.76 |
HEK293T-derived EVs | HEK293T-eGFP cells | fluorescent protein | transfection (calcium phosphate) | Whitley et al.77 | |
HEK293T cells derived EVs | U2OS GFP-negative cells | fluorescent protein | Fugene 6 (Promega) and TurboFect | Wang et al.78 | |
HEK293T cells derived EVs | HEK293T-derived HBB-IL2RG EGFP reporter cells | HBB/IL2RG and DMD exon 53 | Fugene HD (Promega)/polyethylenimine | Yao et al.75 | |
293T cells derived Gectosomes | MEF cells | PINK1 or PCSK9 | transfection (polyethylenimine) | Zhang et al.135 | |
HEK 293T cell-derived exosome | A549stop-DsRed reporter cell line | stop-DsRed | transfection (Lipofectamine 2000) | Ye et al.136 | |
Hepatic stellate cells-derived exosome | Liver | PUMA, CcnE1,(KAT5 | electroporation | Wan et al.137 | |
HEK293T cells | Skeletal muscle cells | DMD | transfection (Lipofectamine 2000) | Gee et al.84 | |
MSCs-derived exosome | HEK293T-EGFP cells | fluorescent protein | Lipofection (chemical) and electroporation (physical) | Hazrati et al.138 | |
Tumor cells | Liver | fluorescent protein | transfection (Lipofectamine 2000) | Ye et al.86 | |
HEK293T | HeLa cell | fluorescent protein | transfection (Endofectin Max reagent) | Strohmeier et al.87 | |
Post-isolation | HEK293T cells-derived | Muscle | DMD | transfection (Lipofectamine 2000) | Watanabe et al.85 |
C2C12 cells | Muscle | miR-29b | transfection (PEI MAX) | Chen et al.89 | |
HEK293T cells-derived | Tumor | WNT10B | sonication/freeze-thaw cycles | Zhuang et al.139 | |
Human or mouse serum | Mouse Muscle | DMD | protein transfectant | Majeau et al.88 |